文献速递乳腺癌

选择性雌激素受体共价拮抗剂治疗ERα野生型与突变型乳腺癌的发现

Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.
PubMed 文献 · Cancer Discov · 2018-07-10

在内分泌治疗复发患者中,高达30%可检出导致耐药的相关ERα突变,且耐药转移灶仍依赖ERα信号。研究通过药物发现获得H3B-5942,其靶向Cys530共价灭活野生型与突变型ERα并诱导独特拮抗构象,属于选择性雌激素受体共价拮抗剂(SERCA)。体外对比显示其对ERα野生型与突变型细胞系的拮抗活性增强;体内在ERα野生型与ERαY537S异种移植模型中单药抗肿瘤活性显著且优于氟维司群;与CDK4/6或mTOR抑制剂联合可进一步提升效力。

要点

  • H3B-5942靶向Cys530共价灭活野生型与突变型ERα,属于SERCA类口服拮抗剂。
  • 体外对ERα野生型与突变型细胞系的拮抗活性优于标准治疗与实验药物。
  • 体内在ERα野生型与ERαY537S模型中单药活性优于氟维司群,联合CDK4/6或mTOR抑制剂可增强效力。

核心结论

  • H3B-5942是口服SERCA,可共价灭活野生型与突变型ERα,体外与体内活性优于标准治疗药物。
  • 在ERα野生型与ERαY537S异种移植模型中,H3B-5942单药抗肿瘤活性显著且优于氟维司群。
  • H3B-5942与CDK4/6或mTOR抑制剂联合可在ERα野生型与突变型细胞系和/或肿瘤模型中进一步提升效力。

研究设计与样本

  • 研究为药物发现与临床前研究,通过药物发现工作识别H3B-5942。
  • 体外比较H3B-5942与标准治疗及实验药物在ERα野生型与突变型细胞系中的拮抗活性。
  • 体内在代表ERα野生型与ERαY537S乳腺癌的异种移植模型中评估单药抗肿瘤活性。

主要发现

  • 在内分泌治疗复发患者中,高达30%可检出导致耐药的ERα突变。
  • H3B-5942靶向Cys530共价灭活野生型与突变型ERα,并强制形成独特拮抗构象。
  • 体外比较显示H3B-5942在ERα野生型与突变型细胞系中拮抗活性增强。
  • 体内H3B-5942在ERα野生型与ERαY537S异种移植模型中单药抗肿瘤活性显著且优于氟维司群。
  • H3B-5942与CDK4/6或mTOR抑制剂联合可在ERα野生型与突变型细胞系和/或肿瘤模型中进一步提升效力。

关键数值与推荐

  • 在内分泌治疗复发患者中,高达30%可检出导致耐药的ERα突变。
  • H3B-5942靶向ERα的Cys530并共价灭活野生型与突变型ERα。
  • H3B-5942属于选择性雌激素受体共价拮抗剂(SERCA)类口服拮抗剂。

临床怎么用

  • 针对内分泌治疗耐药且ERα突变仍依赖ERα信号的乳腺癌,SERCA类口服拮抗剂是潜在治疗方向。
  • 临床前提示H3B-5942可单药使用,并可与CDK4/6或mTOR抑制剂联合以提升效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant proportion of therapy-resistant breast cancer metastases continue to be dependent on ERα signaling, there remains a critical need to develop the next generation of ERα antagonists that can overcome aberrant ERα activity. Through our drug-discovery efforts, we identified H3B-5942, which covalently inactivates both wild-type and mutant ERα by targeting Cys530 and enforcing a unique antagonist conformation. H3B-5942 belongs to a class of ERα antagonists referred to as selective estrogen receptor covalent antagonists (SERCA). In vitro comparisons of H3B-5942 with standard-of-care (SoC) and experimental agents confirmed increased antagonist activity across a panel of ERαWT and ERαMUT cell lines. In vivo, H3B-5942 demonstrated significant single-agent antitumor activity in xenograft models representing ERαWT and ERαY537S breast cancer that was superior to fulvestrant. Lastly, H3B-5942 potency can be further improved in combination with CDK4/6 or mTOR inhibitors in both ERαWT and ERαMUT cell lines and/or tumor models. In summary, H3B-5942 belongs to a class of orally available ERα covalent antagonists with an improved profile over SoCs.Significance: Nearly 30% of endocrine therapy-resistant breast cancer metastases harbor constitutively activating mutations in ERα. SERCA H3B-5942 engages C530 of both ERαWT and ERαMUT, promotes a unique antagonist conformation, and demonstrates improved in vitro and in vivo activity over SoC agents. Importantly, single-agent efficacy can be further enhanced by combining with CDK4/6 or mTOR inhibitors. Cancer Discov; 8(9); 1176-93. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 1047.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Puyang X, Furman C, Zheng GZ, et al. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. Cancer Discov. 2018. PMID: 29991605. doi:10.1158/2159-8290.CD-17-1229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。